Reporter brief
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The clinical efficacy of senolytics for cognitive outcomes—this was a Phase II feasibility study, not a pivotal trial powered for efficacy. The generalizability to broader populations with Alzheimer's disease or cognitive decline, as the study enrolled only tau PET-positive individuals with specific disease stages. Whether senolytic effects on cellular aging markers translate to clinical benefit in neurodegenerative disease.
Study design and sample
Rct; Human.
Not recorded.
- Design
- Rct
- Sample
- —
- Journal
- Washington University School of Medicine
- Published
- Apr 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.